# Avitia

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/avitia

- Industry: Biotechnology
- Headquarters: Montreal, Canada
- Website: www.avitia.bio
- Total disclosed funding: $3.5M
- Latest round: Seed (Feb 27, 2025)
- Investors on record: 1

## About

Avitia is a biotechnology company that develops innovative solutions for healthcare and agriculture, aiming to enhance therapeutic outcomes and improve crop resilience through advanced biopharmaceuticals and agricultural bioproducts.Avitia is engaged in biotechnology, focusing on developing solutions for healthcare and agriculture. Founded in 2025 in Montreal, Canada, the company has completed one deal to date. The most recent deal occurred on February 27, 2025, when Avitia raised USD 5.00 mn in Seed funding led by PacBridge Capital Partners. No changes in business operations or pivots have been mentioned.Avitia Bio focuses on developing innovative biotechnology solutions aimed at addressing critical challenges in healthcare and agriculture. Their core product offerings include advanced biopharmaceuticals designed to enhance therapeutic outcomes for patients suffering from chronic diseases. Additionally, they provide agricultural bioproducts that improve crop resilience and yield, catering to the growing needs of sustainable farming. Avitia Bio primarily serves healthcare providers, pharmaceutical companies, and agricultural firms, focusing on markets in North America, Europe, and select regions in Asia. These products were released over the past few years, with a strong emphasis on integrating cutting-edge research to ensure efficacy and safety for end users, including patients and farmers.Avitia Bio generates revenue through a combination of direct sales and strategic partnerships within the biopharmaceutical and agricultural sectors. The company has established a transactional framework that includes B2B sales to healthcare organizations and agricultural distributors, facilitating streamlined access to its flagship biopharmaceuticals and agricultural products. Revenue is derived from various models, including subscription-based agreements for ongoing supply and support, as well as one-time purchases. Specific pricing plans for Avitia Bio's offerings incorporate tiered structures that reflect the complexity and value of their products, allowing for flexibility in customer engagement. This transactional approach positions Avitia Bio favorably within the market, ensuring robust revenue streams aligned with their innovative product lines.In February 2025, Avitia raised USD 5.00 mn in Seed funding led by PacBridge Capital Partners. The company plans to utilize this funding to expand into new global markets and enhance its artificial intelligence-powered platform. Notably, they are developing liquid biopsy solutions aimed at improving cancer monitoring and early recurrence detection. Avitia aims to introduce these products and expand their market presence significantly by the end of 2026.

## Funding rounds

- Seed, Feb 27, 2025, $3.5M — PacBridge Capital Partners

## Investors

- PacBridge Capital Partners (https://capitalatlas.ai/funds/pacbridge-capital-partners) — Seed